Logo
x

Search

Subscribe Now

CNS Disorders

Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders

Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS...

  • October 21, 2021
Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

  • March 19, 2021
Shionogi to Acquire Tetra Therapeutics for ~$500M

Shionogi to Acquire Tetra Therapeutics for ~$500M

  • May 27, 2020
Regeneron Collaborates with Alnylam to Discover- Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Regeneron Collaborates with Alnylam to Discover- Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

  • April 9, 2019
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders

Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders

  • February 7, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.